SS-31 vs FOXO4-DRI
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Elamipretide, Bendavia
A mitochondria-targeted peptide that improves cellular energy production. FDA approved for Barth syndrome (September 2025) as FORZINITY, the first approved mitochondria-targeted therapeutic.
Also: FOX04-DRI, FOXO4 D-Retro-Inverso
A senolytic peptide designed to selectively eliminate senescent 'zombie' cells by disrupting the FOXO4-p53 interaction. Shows promise for restoring tissue function in aging, including kidney health restoration.
Key Comparison Insights
- SS-31 is FDA approved, while FOXO4-DRI remains in research stages.
- Both peptides belong to the Anti-Aging category, suggesting similar primary applications.
- SS-31 has stronger research evidence (FDA Approved) compared to FOXO4-DRI (Animal Studies).
Detailed Comparison
| Attribute | SS-31 | FOXO4-DRI |
|---|---|---|
| Category | Anti-Aging | Anti-Aging |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | SS-31 concentrates 1000-fold in mitochondria, binding to cardiolipin on the inner membrane. It optimizes electron transport chain function, reduces reactive oxygen species, and prevents cardiolipin peroxidation during cellular stress. | FOXO4-DRI is a D-retro-inverso peptide that interferes with the binding between FOXO4 and p53 proteins. In senescent cells, FOXO4 binds to p53 to prevent apoptosis, allowing these dysfunctional cells to persist. FOXO4-DRI competes for this binding, releasing p53 to trigger apoptosis specifically in senescent cells while sparing healthy cells. |
| Common Dosing | 40 mg subcutaneous daily Once daily | 2-10 mg every other day for 3 doses (one cycle) 3 doses every other day, 1-3 cycles per year |
| Administration | Subcutaneous injection or IV infusion | Subcutaneous injection (community), IV/IP in animal studies |
| Typical Duration | Variable by condition | 1 cycle = 3 doses over 5-6 days, repeat 1-3x yearly |
| Best Time to Take | Morning | Per research protocol |
Possible Side Effects May vary by individual |
|
|
| Research Summary | FDA approved for Barth syndrome in September 2025 under accelerated approval. Ongoing trials for dry age-related macular degeneration and primary mitochondrial myopathy. Studies show improved cardiac function, exercise capacity, and mitochondrial efficiency. | Landmark 2017 Cell study demonstrated that FOXO4-DRI restored fitness, fur density, and renal function in aged mice. Studies show improved kidney tubular cell markers, better urea/creatinine metrics, and reduced SASP (senescence-associated secretory phenotype) cytokines. A 2025 Nature Communications study provided detailed structural insights into the FOXO4-p53 interaction mechanism. Cleara Biotech is developing FOXO4-DRI for conditions including kidney disease, COPD, and osteoarthritis. |
Frequently Asked Questions: SS-31 vs FOXO4-DRI
What is the difference between SS-31 and FOXO4-DRI?
SS-31 is a anti-aging peptide that a mitochondria-targeted peptide that improves cellular energy production. fda approved for barth syndrome (september 2025) as forzinity, the first approved mitochondria-targeted therapeutic. FOXO4-DRI is a anti-aging peptide that a senolytic peptide designed to selectively eliminate senescent 'zombie' cells by disrupting the foxo4-p53 interaction. shows promise for restoring tissue function in aging, including kidney health restoration. The main differences lie in their mechanisms of action and clinical applications.
Which is better, SS-31 or FOXO4-DRI?
Neither is universally "better" - the choice depends on your specific goals. SS-31 is typically used for anti-aging purposes, while FOXO4-DRI is used for anti-aging. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can SS-31 and FOXO4-DRI be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using SS-31 and FOXO4-DRI together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.